$21.88
▲ +0.6% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
3 Reasons to Avoid BAX and 1 Stock to Buy Instead
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
Goldman Sachs Adjusts Price Target on Baxter International to $21 From $19, Maintains Neutral Rating
Overview
52-week range
$16
$32
38% of range
Avg surprise (last 2)
+6.5%
Avg reaction (last 1)
-1.6%
0% positive
Latest IV / EM
74%
EM ±9.3% · $22 · Jul 31
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.03 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.09 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $0.59 | $0.60 | -1.7% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $0.55 | $0.48 | +14.6% | — | -1.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.27 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.61 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $4.93 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.28 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | $0.36 | $0.59 | -39.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.70B | — | $2.83B | $2.81B | $2.62B | — | $2.70B | $2.69B |
| Cost of revenue | $1.81B | — | $1.89B | $1.82B | $1.76B | — | $1.67B | $1.66B |
| Gross profit | $891M | — | $950M | $991M | $861M | — | $1.03B | $1.03B |
| Operating income | $66M | — | $172M | $191M | $58M | — | $155M | $179M |
| Net income | $-15M | — | $-46M | $91M | $126M | — | $140M | $-314M |
| EPS (diluted) | $-0.03 | — | $-0.09 | $0.18 | $0.25 | — | $0.27 | $-0.61 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.02B | $1.97B | $1.73B | $1.69B | $2.29B | $1.76B | $1.42B | $1.57B |
| Inventory | $2.32B | $2.23B | $2.46B | $2.38B | $2.17B | $2.05B | $2.10B | $2.98B |
| Total current assets | $6.85B | $6.87B | $6.93B | $6.75B | $7.04B | $8.85B | $8.86B | $8.59B |
| Total assets | $19.85B | $20.05B | $21.07B | $21.05B | $21.30B | $25.78B | $26.68B | $26.31B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13.83B | $13.95B | $13.85B | $13.75B | $14.25B | $18.76B | $18.73B | $18.60B |
| Total equity | $6.04B | $6.13B | $7.24B | $7.32B | $7.08B | $6.96B | $7.87B | $7.64B |